Navigation Links
Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01
Date:7/26/2011

11.8Global Generics net revenue for the second quarter 2011 increased 39 percent to $792.4 million due to increased sales of extended-release products, primarily as a result of the launch of methylphenidate ER during the quarter.  Extended release product sales were $380.1 million, up 138 percent from the second quarter 2010 as a result of the launch of methylphenidate ER and higher sales of metoprolol succinate ER.  Second quarter international net revenue was $119.2 million, up eight percent from the second quarter 2010, as a result of the addition of Specifar Pharmaceuticals in May.

Global Generics adjusted gross margin decreased 3.4 percentage points to 45.2 percent in the second quarter 2011.  Adjusted Global Generics gross margin was negatively impacted by the launch of methylphenidate ER.

Global Generics R&D investment for second quarter 2011 increased 31 percent to $58.3 million, primarily due to increased clinical study costs and increased investment in international R&D.  Six new products were launched in the U.S. and we had seven new patent challenges during the quarter.

Global Brands Segment InformationThree Months EndedJune 30,Six Months EndedJune 30,(Unaudited; $ in millions)

2011201020112010Product sales

$
92.0$
76.9$
72.3$
49.3Other revenue

20.926.637.545.5Net revenue

112.9103.5209.8194.8Operating expenses:Cost of sales

25.123.642.948.3Research and development

22.217.242.134.5Selling and marketing

44.835.481.367.9Segment contribution

$
20.8$
27.3$
43.5$
44.1Segment margin

18.4%26.4%20.7%22.6%Gross profit

$
87.8$
79.9$
.9$
46.5Gross margin

77.8%77.2%79.6%75.2%Global Brands net revenue increased nine percent to $112.9 million in the second quarter 2011 as a result of the addition of new products including Crinone®, Generess™ Fe and Nulecit™ and increased sales of RAPAF
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Watson Confirms JALYN™ Patent Challenge
2. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
3. Watson Confirms Vyvanse® Patent Challenge
4. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings
5. Watson Announces Expansion of Salt Lake City, Utah Pharmaceutical R&D and Manufacturing Facility
6. Watson to Present at 2011 Wells Fargo Securities Healthcare Conference
7. Watson Confirms AVODART(R) Patent Challenge
8. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
9. Watsons Nabumetone Tablets Receive FDA Approval
10. Watson Confirms Pataday™ Patent Challenge
11. Watson Confirms Viagra® Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CVS Caremark Corporation (NYSE: CVS ) announced today ... in connection with its previously announced cash tender offers (the ... and all of its 6.250% Senior Notes due 2027 (the ... amount of its 6.125% Senior Notes due 2039, 5.750% Senior ... the "Maximum Tender Offer Notes" and together with the Any ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... , Aug. 21, 2014  SI-BONE, Inc. ( ... that pioneered the use of the iFuse Implant System, ... for fusion of the sacroiliac (SI) joint, announced that ... update to its Lumbar Fusion Medical Policy No. 91590-R4 ... procedure.  The policy states that the fusion procedure, which ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:8/21/2014)... considered nearly eradicated. Each year only a few hundred ... of Bonn, together with colleagues from Gabon, are reporting ... resist the vaccine protection to a considerable extent was ... in 2010. The pathogen could also potentially have infected ... the magazine PNAS . , The polio epidemic ...
(Date:8/21/2014)... Maryland (PRWEB) August 21, 2014 As ... the U.S. Pharmacopeial Convention (USP) has joined with the ... threat posed by the illegal online sale of medicines. ... benefits of medicines and foods is a core mission ... health around the world,” said Ronald T. Piervincenzi, chief ...
(Date:8/21/2014)... It's a terrible thing when a young adult, ... substance abuse issue. When that happens to a teenager in ... reliable help from the qualified substance abuse therapists at a ... easy for those young adults living in Pompano Beach, FL ... , Thankfully there is a new helpline operating for ...
(Date:8/21/2014)... CA (PRWEB) August 21, 2014 David ... is a short but powerful collection of quotes from ... uplift and inspire other budding entrepreneurs on their challenging ... proud to announce the inclusion of President and Founder ... from highly successful and self-made celebrities such as Oprah ...
(Date:8/21/2014)... by T-type calcium channels in the thalamic reticular ... calcium. These channels enable thalamic reticular nucleus neurons ... enter a hyper-excited state. , In order to ... seizures, the researchers conducted an experiment to induce ... to delete the T-type calcium channel CaV3.3. The ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2
... , FRIDAY, July 29 (HealthDay News) -- Some ethnic groups are ... organs as they gain weight, according to a new study. ... artery disease, is more common among people from South Asia, the ... journal PLoS ONE . "The new study showed South ...
... may also be contributing to hearing loss. Scientists mapped ... The distinctive roar of a Harley,s engine is ... noise for motorcyclists is actually generated by air whooshing ... sound can exceed safe levels. Now, scientists have identified ...
... testing at local emergency departments shows that hospitals miss opportunities ... with HIV, even when a regular testing program is in ... to the July issue of Annals of Emergency Medicine ... (CDC). The supplement includes a series of studies on HIV ...
... When people recognize voices, part of what helps make ... differently. But individuals with dyslexia don,t experience this familiar ... impairment." Tyler Perrachione with the Massachusetts Institute of ... language use the same words, they say those words ...
... protect skin cells from the sun,s ultraviolet radiation, according ... Barcelona and the CSIC (Spanish National Research Council). The ... in sun protection products. Ultraviolet (UV) rays emitted ... skin complaints, causing skin cancer, sunburn and solar erythema, ...
... The U.S. Food and Drug Administration should gather the ... the 35-year-old 510(k) clearance process for medical devices, says a ... process lacks the legal basis to be a reliable premarket ... devices and cannot be transformed into one, concluded the committee ...
Cached Medicine News:Health News:Some Ethnic Groups More Vulnerable to Dangerous Fat 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 3Health News:Dissecting dyslexia: Linking reading to voice recognition 2Health News:Dissecting dyslexia: Linking reading to voice recognition 3Health News:Grapes protect against ultraviolet radiation 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: